Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release
Posted in Healthcare, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alexion, amyloid fibril deposits, amyloidosis, AstraZeneca, ATTR-CM, cardiomyopathies, Heart, heart failure, human monoclonal antibody, licence agreement, Marc Dunoyer, misfolded transthyretin, Neurimmune AG, NI006, rare disease, transthyretin amyloid cardiomyopathy
(PRESS RELEASE) PARIS/ CAMBRIDGE, 11-Jan-2021 — /EuropaWire/ — French multinational pharmaceutical company Sanofi to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics. The agreement includes an upfront payment … Read the full press release
Posted in France, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, antibody for inflammatory disorders, antibody technologies, atopic dermatitis, biopharmaceutical, biopharmaceutical company, EASI, Eczema Area and Severity Index, fully human antibodies, Goodwin PLC, Gotshal & Manges LLP, human monoclonal antibodies, human monoclonal antibody, ICOS agonist monoclonal antibody, immune regulator, immune-mediated diseases, immuno-oncology therapeutics, inflammatory disorders, J.P. Morgan, John Reed M.D. Ph.D., KY1005, KY1044, Kymab, novel therapies, OX40-Ligand, OX40L, Paul Hudson, Sanofi, Simon Sturge, topical corticosteroids, Weil
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
